the Fetal Epicardial Thickness in Obese Pregnant Women (EFT)
Study Details
Study Description
Brief Summary
the effects of fetal EFT on fetal cardiac function and fetal and maternal outcomes were investigated in obese pregnant women compared with normal-weight pregnant women.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
All pregnant women underwent a comprehensive fetal anomaly screening. One obstetrician (S.D.) assessed all of the measurements. Every measurement was performed using a convex 2-5 MHz Voluson E8 probe (GE Healthcare, Milwaukee, WI). Fetal biometry, UA, MCA Doppler, cerebroplacental ratio (CPR), modified MPI (mod-MPI), and EFT were assessed in accordance with the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) guidelines
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: myocardial performance and epicard thickness in obese pregnant women obese pregnant versus normal-weight pregnant women were evaluated for MPI and fetal epicardial thickness |
Diagnostic Test: Doppler ultrasonography
Doppler study was performed in all cases. perinatal outcomes were evaluated.
|
Active Comparator: obese pregnant obese pregnant versus normal-weight pregnant women were evaluated for MPI and fetal epicardial thickness |
Diagnostic Test: Doppler ultrasonography
Doppler study was performed in all cases. perinatal outcomes were evaluated.
|
Outcome Measures
Primary Outcome Measures
- birth weight (gram) [birth 1 week]
fetal outcome
- stillbirth rate (%) [birth 1 week]
fetal outcome
- NICU admission [6 months]
fetal outcome
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Obese pregnant women
-
normal-weight pregnant women
-
24-40 gestational week
Exclusion Criteria:
Twin pregnancies, structural and chromosomal abnormalities, fetal rhesus isoimmunization, fetal growth restriction, cases with infections detected by maternal serological tests, pregestational or gestational diabetes (All patients underwent a 75-gram glucose load test at 24 weeks to rule out diabetes), preeclampsia, premature rupture of membranes were excluded from the study -
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Necmettin Erbakan University | Konya | Turkey | 42140 |
Sponsors and Collaborators
- Necmettin Erbakan University
Investigators
- Study Director: şükran DR doğru, md, NECMETTİN ERBAKAN UNIVERCITY
- Principal Investigator: fatih dr akkuş, md, NECMETTİN ERBAKAN UNIVERCITY
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 14221/neu